Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

847
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

452
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
452
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

513
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
513
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.0K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.0K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.7K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.7K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain health awareness among solid organ transplant candidates and recipients: a single centre survey.

BMC neurology·2026
Same author

Physicochemical Stability of Dentin-Derived Biomaterials During Long-Term Storage.

Journal of functional biomaterials·2026
Same author

Reply to: Effect of endoscopic pre-aponeurotic repair of diastasis recti on gastroesophageal reflux symptoms.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Ultrasound-guided percutaneous stellate ganglion block for refractory atrial fibrillation.

Minerva anestesiologica·2026
Same author

<i>HSD17B4</i>-Related Disorder: Defining the Phenotype in Adult-Onset Patients.

Neurology. Genetics·2026
Same author

Ataxia With Vitamin E Deficiency Syndrome and a Novel <i>TTPA</i> Variant: A Paired Case Report.

Neurology. Genetics·2026

Related Experiment Video

Updated: Sep 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Statins Neuromuscular Adverse Effects.

Silvia Attardo1, Olimpia Musumeci1, Daniele Velardo2

  • 1Unit of Neurology and Neuromuscular Disorders, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.

International Journal of Molecular Sciences
|August 12, 2022
PubMed
Summary

Statins, commonly used for cardiovascular health, can cause significant neuromuscular side effects. Early detection and management, including potential drug cessation, are crucial for patient safety and preventing muscle damage.

Keywords:
muscle adverse effectsmyasthenianeuromuscular complicationsperipheral neuropathystatins and myopathy

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.8K

Related Experiment Videos

Last Updated: Sep 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.8K

Area of Science:

  • Neurology
  • Pharmacology
  • Cardiology

Background:

  • Statins are widely prescribed for cardiovascular disease prevention.
  • Neuromuscular adverse events constitute a significant portion of statin-related side effects.
  • These effects range from myalgia to severe conditions like rhabdomyolysis.

Purpose of the Study:

  • To review current knowledge on statin-associated neuromuscular adverse effects.
  • To discuss diagnosis and management strategies for these complications.
  • To highlight the increasing relevance due to widespread statin use.

Main Methods:

  • Literature review of statin-associated neuromuscular adverse effects.
  • Analysis of clinical follow-up data and management strategies.
  • Synthesis of information on diagnosis and prevention.

Main Results:

  • Neuromuscular side effects are common, including cramps, myalgia, weakness, myopathy, and neuropathy.
  • Statins can also induce or unmask neuromuscular junction dysfunction.
  • Statin cessation or alternative lipid-lowering agents can mitigate these effects.

Conclusions:

  • Increased statin use necessitates greater awareness of neuromuscular complications.
  • Early clinical monitoring is vital for identifying and managing statin-induced neuromuscular damage.
  • Pharmacogenomic and environmental studies are expected to enable personalized therapeutic approaches to predict and prevent these adverse events.